Navigation Links
Mylan Confirms Four First-to-File Challenges
Date:3/26/2009

PITTSBURGH, March 26 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced that it and/or a subsidiary have been sued in connection with four separate "first-to-file" Abbreviated New Drug Applications (ANDA) filed with the U.S. Food and Drug Administration (FDA).

Mylan and Alphapharm Pty. Ltd were sued by Sepracor Inc. in the U.S. District Court of New Jersey in connection with the ANDA filing for Eszopiclone Tablets, 1 mg, 2 mg and 3 mg. Eszopiclone Tablets are the generic version of Sepracor's insomnia treatment Lunesta(R) Tablets, which had approximately $796 million in U.S. sales for the twelve months ending Dec. 31, 2008, according to IMS Health.

Mylan Pharmaceuticals Inc. was sued by OSI Pharmaceuticals Inc., Pfizer Inc. and Genentech Inc. in the U.S. District Court in Delaware in connection with the ANDA filing for Erlotinib Hydrochloride (HCl) Tablets, 25 mg, 100 mg and 150 mg. Erlotinib HCl Tablets are the generic version of OSI Pharmaceuticals' lung cancer treatment Tarceva(R) Tablets, which had approximately $492 million in U.S. sales for the twelve months ending Dec. 31, 2008, according to IMS Health.

Mylan, Mylan Pharmaceuticals and Matrix Laboratories Limited, in which Mylan owns a majority interest, were sued by Shire Canada Inc., Shire International Licensing B.V. and Shire U.S. Inc. in the U.S. District Court for the Southern District of New York in connection with the ANDA filing for Lanthanum Carbonate Chewable Tablets, 500 mg, 750 mg and 1000 mg. Lanthanum Carbonate Chewable Tablets are the generic version of Shire's kidney disease treatment Fosrenol(R), which had approximately $108 million in U.S. sales for the twelve months ending Dec. 31, 2008, according to IMS Health.

Mylan Pharmaceuticals was sued by Galderma Laboratories Inc., Galderma Laboratories LP, The Research Foundation of the State University of New York and New York University in the U.S. District Court of Delaware in connection with the ANDA filing for Doxycycline Delayed-release (DR) Capsules USP, 40 mg. Doxycycline DR Capsules are the generic version of Galderma's adult rosacea treatment Oracea(R) Capsules, which had approximately $82 million in U.S. sales for the twelve months ending Dec. 31, 2008, according to IMS Health.

Mylan believes it is among the first companies to have filed substantially complete ANDAs containing a Paragraph IV certification for three of these products and expects to be awarded 180 days of shared marketing exclusivity once final approvals are obtained. With Doxycycline DR Capsules, Mylan believes it could have sole marketing exclusivity for the 180 day period. Currently, Mylan has 118 ANDAs pending FDA approval, 33 of which are potential first-to-file opportunities.

This press release includes statements that constitute "forward-looking statements," including with regard to the expected first to file status and pending litigation. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward- looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the use of legal, regulatory and legislative strategies by competitors or other third parties to delay or prevent product introductions; risks inherent in legal and regulatory processes; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies.


'/>"/>
SOURCE Mylan Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
2. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
3. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
4. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
5. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
6. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
7. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
10. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
11. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... LATHAM, NEW YORK... Marktech Optoelectronics will feature their ... in San Francisco’s Moscone Center from February 16-18, 2016, and at the healthcare-focused BiOS ... InGaAs PIN diode standard packages feature a TO-46 metal can with active areas of ...
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare Medical, LLC reports ... program, Sonalink™ remote monitoring. The inaugural launch of this new technology occurred over ... Dr. Samuel Peretsman to a HIFU technical expert at SonaCare Medical headquarters. ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... a research registry built on the secure online PatientCrossroads platform, has exceeded both ... 1,600 participants have joined the PROMPT study, which seeks to advance understanding of ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... ... is now available on Microsoft Azure. On Azure, Arvados provides capabilities for managing ... saw clear demand for Microsoft Azure from major institutions collecting and analyzing genomic ...
Breaking Biology Technology:
(Date:2/10/2016)... , February 10, 2016 ... According to 2016 iris recognition market report, ... recognition is more widely accepted for border ... both fingerprint and iris recognition technology in ... to avoid purchasing two individual biometrics devices. ...
(Date:2/9/2016)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... fourth quarter and year ended December 31, 2015.  ... of 2015 was $6.9 million, an increase of 61% compared to ... the fourth quarter of 2015 was $2.6 million compared to $0.2 ... --> --> Higher revenue and operating income in ...
(Date:2/9/2016)... , Feb. 9, 2016 Vigilant Solutions announces today ... reader (LPR) to develop a lead in a difficult homicide ... LPR data to locate the suspect vehicle. Due to the ... case have been omitted at the agency,s request. ... agency explains, "Our victim was found deceased at an intersection ...
Breaking Biology News(10 mins):